Description:
Lung cancer is the leading cause of cancer deaths worldwide, in part because of chemo-resistance. Using a combination therapy with a novel CRM1 inhibitor has shown to prolong survival for lung cancer. Research has shown very low doses of the inhibitor administered with traditional chemotherapeutic agents reduce toxicity effects compared to other treatments, while extending survival.
Reference Number: D-0928
Market Applications:
Therapeutics
Features, Benefits, and Advantages:
The novel addition of CRM1 (chromosome maintenance region 1) inhibitors, to current treatment regimens of cisplatin and doxorubicin increase cytotoxicity in vitro. A very low, non-toxic dose was tested in the laboratory and showed astounding results in inhibiting lung cancer cell growth in vivo.
- This combination has shown to be more efficacious in in vivo than traditional treatments for lung cancer.
- The strength of response is surprising, given the small amount of inhibitor administered.
- Therapy with the inhibitor may have significance in other types of cancer.
Intellectual Property:
A U.S. national stage patent application 15/313,339 was filed on 11/22/2016.
Development Stage:
Mice work has been completed, in preparation for clinical trial, and data is available upon request.
Publications:
Open Access Publication, March 2012, “Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with Doxorubicin.”
Researcher:
Weimin Gau, The Institute of Environmental and Human Health, Texas Tech University